Sympatholysis and cardiac sympathetic nerve function in the treatment of congestive heart failure

Journal of the American College of Cardiology

Volumn 42, Issue 3, 2003, Pages 549-551

  Liang, Chang Seng ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; CLONIDINE; DESIPRAMINE; ENALAPRIL; GUANABENZ; GUANETHIDINE; METOPROLOL; MONOCROTALINE; MOXONIDINE; NORADRENALIN; SELEGILINE; SPIRONOLACTONE;

ADRENERGIC ACTIVITY; ADRENERGIC SYSTEM; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG RESPONSE; DRUG SCREENING; EDITORIAL; FUNCTIONAL ASSESSMENT; HEART INNERVATION; HEART LEFT VENTRICLE CONTRACTION; HEART NERVE; HUMAN; MORTALITY; NERVE FUNCTION; NONHUMAN; NORADRENALIN RELEASE; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL; SYMPATHETIC NERVE;

EID: 0042628118     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00643-0     Document Type: Editorial

References (35)

1. Chidsey CA, Harrison DC, Brunwald E. Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure. N Engl J Med 1962;267:650-4.
2. Bristow MR. β-Adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-69.
3. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
4. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomized trial. Lancet 1999;353:9-13.
5. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Chronic Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
6. 1-imidazoline receptor agonist. J Cardiovasc Pharmacol 1996;27 Suppl 3:S26-37.
7. Dickstein K, Manhenke C, Aarsland T, Køff U, McNay J, Wiltse C. Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83:1638-44.
8. Swedberg K, Bristow MR, Cohn JN, et al., for the Moxonidine Safety and Efficacy (MOXSE) investigators. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 2002;105:1797-803.
9. Azevedo ER, Newton GE, Parker JD. Cardiac and systemic sympathetic activity in response to clonidine in human heart failure. J Am Coll Cardiol 1999;33:186-91.
10. Coats AJ. Heart Failure 99: the MOXCON story. Int J Cardiol 1999;71:109-11.
11. Bristow M, Krause-Steinrauf H, Abraham WT, et al. Sympatholytic effect of bucindolol adversely affected survival, and was disproportionately observed in the class IV subgroup of BEST (abstr). Circulation 2001;104 Suppl II:II755.
12. Igawa A, Nozawa T, Fujii N, Kato B-i, Asanoi H, Inoue H. Long-term treatment of low-dose, but not high-dose, guanethidine improves ventricular function and survival of rats with heart failure after myocardial infarction. J Am Coll Cardiol 2003;42:541-8.
13. Packer M, Coats AJS, Fowler MB, et al., for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failur. N Engl J Med 2001;344:1649-58.
14. Schmidt RF, Summerfield AL, Hickey WF. Ultrastructural and immunohistologic characterization of guanethidine-induced destruction of peripheral sympathetic neurons. J Neuropathol Exp Neurol 1990;49:150-67.
15. Hougen HP, Thygesen P, Christensen HB, Rygaard J, Svendsen O, Juul P. Effect of immunosuppressive agents on the guanethidine-induced sympathectomy in athymic and euthymic rats. Int J Immunopharmacol 1992;14:1113-23.
16. Henderson EB, Kahn JK, Corbett JR, et al. Abnormal 1-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988;78:1192-9.
17. Merlet P, Benvenuti C, Moyse D, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999;40:917-23.
18. 123I-metaiodobenzylguanidine uptake. J Nucl Med 2001;42:49-54.
19. de Milliano PAR, de Groot AC, Tijssen JGP, van Eck-Smit BLF, Van Zwieten PA, Lie KI. Beneficial effects of metoprolol on myocardial sympathetic function: evidence from a randomized, placebo-controlled study in patients with congestive heart failure. Am Heart J 2002;144:E3.
20. Kasama S, Toyama T, Kumakura H, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002;43:1279-85.
21. 123I]-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure. Heart 1996;76:218-22.
22. The Beta-Blocker Evaluation of Survival Trial investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
23. Eichhorn EJ, McGhie AL, Bedotto JB, et al. Effects of bucindolol on neurohormonal activation in congestive heart failure. Am J Cardiol 1991;67:67-73.
24. Fan THM, Liang C-s, Kawashima S, Banerjee SP. Alterations in cardiac β-adrenergic receptor responsiveness and adenylate cyclase system by congestive heart failure in dogs. Eur J Pharmacol 1987;140:123-32.
25. Liang C-s, Fan THM, Sullebarger JT, Sakamoto S. Decreased adrenergic neuronal uptake activity in experimental right heart failure: a chamber-specific contributor to beta-adrenoceptor down-regulation. J Clin Invest 1989;84:1267-75.
26. Himura Y, Felten SY, Kashiki M, Lewandowski TJ, Delehanty JM, Liang C-s. Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive heart failure. Circulation 1993;88:1299-309.
27. Delehanty JM, Himura Y, Elam H, Hood WB Jr., Liang C-s. β-Adrenoceptor downregulation in pacing-induced heart failure is associated with increased interstitial NE content. Am J Physiol Heart Circ Physiol 1994;266:H930-5.
28. Kawai H, Mohan A, Hagen J, et al. Alterations in cardiac adrenergic terminal function and β-adrenoceptor density in pacing-induced heart failure. Am J Physiol Heart Circ Physiol 2000;278:H1708-16.
29. Dong E, Yatani A, Mohan A, Liang C-s. Myocardial β-adrenoceptor down-regulation by norepinephrine is linked to reduced norepinephrine uptake activity. Eur J Pharmacol 1999;384:17-24.
30. Leineweber K, Brandt K, Wludyka B, et al. Ventricular hypertrophy plus neurohumoral activation is necessary to alter the cardiac β-adrenoceptor system in experimental heart failure. Circ Res 2002;91:1056-62.
31. Leineweber K, Seyfarth T, Broddie OE. Chamber-specific alterations of noradrenaline uptake (uptake1) in right ventricles of monocrotaline-treated rats. Br J Pharmacol 2000;131:1438-44.
32. Liang C-s, Himura H, Kashiki M, Stevens SY. Differential pre- and post-synaptic effects of desipramine on cardiac sympathetic nerve terminals in RHF. Am J Physiol Heart Circ Physiol 2002;283:H1863-72.
33. Shite J, Dong E, Kawai H, Stevens SY, Liang C-s. Selegiline improves cardiac noradrenergic nerve terminal function and β-adrenergic responsiveness in heart failure. Am J Physiol Heart Circ Physiol 2000;279:H1283-90.
34. 2-adrenoceptor agonist guanabenz in rats with aortic constriction. J Cardiovasc Pharmacol 1999;33:409-13.
35. 2-adrenoceptor subtypes prevents progression of heart failure. Circulation 2002;106:2491-6.